Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease.

AIDS. 1998 Aug 20;12(12):1427-36. Unique Identifier : AIDSLINE MED/98394546
Haas G; Samri A; Gomard E; Hosmalin A; Duntze J; Bouley JM; Ihlenfeldt HG; Katlama C; Autran B; Department of Molecular Biology, Max-Planck-Institut fur; Infektionsbiologie, Berlin, Germany.

Abstract: OBJECTIVES: To determine immunodominant regions and new epitopes for cytotoxic T cells (CTL) directed against the HIV-1 pol products reverse transcriptase (RT), integrase and protease in a large cohort of patients at different stages of disease. DESIGN AND METHODS: Cross-sectional analysis of 98 patients from the French IMMUNOCO cohort (CD4 counts: 125-1050 x 10(6) cells/l), monitored for CTL recognition of HIV-1 pol products using recombinant vaccinia virus constructs and synthetic peptides. RESULTS: Memory CTL responses against HIV-1 pol products were detected in 78% of all patients whatever the stage of disease. RT was more immunogenic (81%, 30 out of 37 patients) than integrase and protease (51% and 24%, respectively). CTL recognition of RT was more frequent against Pol amino acids 310-460 (61%, 11 out of 18 patients) than against the other three portions (Pol 168-310, Pol 450-600, Pol 590-728) in patients with CD4 counts > 400 x 10(6)/l, whereas in patients at advanced stages no prominent differences were observed. Two new clusters of antigenic regions were found in the NH2 segment: three epitopes between amino-acids Pol 200 and 217 and four epitopes between amino-acids Pol 346 and 387, using five different HLA-restricting elements. A new cluster of three conserved epitopes was found in the COOH segment of RT. CONCLUSIONS: This study shows that memory CTL responses against HIV-1 RT, integrase and protease are detectable in most patients at different stages of disease. The capacity of CTL to recognize simultaneously clusters of epitopes may become important for the immune control to reinforce antiretroviral drug efficiency.

Keywords: JOURNAL ARTICLE Cohort Studies Epitopes Gene Products, pol/IMMUNOLOGY Human HIV Integrase/*IMMUNOLOGY HIV Protease/*IMMUNOLOGY HIV-1 Reverse Transcriptase/*IMMUNOLOGY Immunodominant Epitopes Immunologic Memory Peptides/CHEMICAL SYNTHESIS/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY Vaccinia Virus/GENETICS
990130
A9911039

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .